Sands Capital closed Global Innovation Fund III at $1.1 billion in March 2026, above its $1.0 billion target and described the fund as oversubscribed. Publicly disclosed LP anchors were Canada Pension Plan Investment Board (CPP Investments) and funds managed by Hamilton Lane; Sands also said the close was supported by existing LPs and drew interest from technology company founders and executives, though those additional LPs were not publicly named.

Read more

The latest publicly announced close from Glade Brook is the Glade Brook Gondola Fund, which closed at over $1 billion in March 2026. Glade Brook also filed a Form D for Strategic Growth V LP on February 5, 2026, but that filing showed $0 sold at the time of filing; I’m therefore treating Gondola as the latest closed fund for LP analysis purposes.

Read more

What happened: Updata Partners (Washington, D.C.) announced the final close of Updata Partners VIII, L.P. at $875M hard cap, meaningfully oversubscribed and closed in ~6 months.

Why LPs care: Updata is a capital-efficient B2B software growth equity platform positioned between venture and buyout with an explicit focus on founder-led / bootstrapped companies and a deal-structuring toolkit designed for downside protection.

1) Quick Take

Updata VIII is not a “frontier AI model” fund. It’s best understood as an allocator-friendly way to underwrite exposure to:

• AI-enabled B2B software where AI acts as a feature/GTМ accelerator, not the entire product.

• Data / analytics / infrastructure-adjacent software that benefits from AI-driven demand: integration, observability, security automation, cloud ops...

• A capital-efficiency tilt often first institutional that can matter in a market where growth at any price has been structurally de-emphasized.

Read more

Quantonation is one of the most established specialist managers dedicated to quantum + deep-physics venture, and just closed a materially larger Fund II (€220M). The key LP question: does a larger, more “industrialization-ready” quantum thesis translate into better risk-adjusted outcomes vs. the prior pioneer era?

Read more

What happened

Thrive Capital announced the close of Thrive X, with total capital “exceeding $10 billion”. The firm states the raise is split into $1B for early-stage and $9B for growth-stage investing.

Read more

1) Fund facts (what an LP needs upfront)

• Manager: nvp capital (NYC)

• Fund: Fund II (closed at $80M; firm states total AUM ~$200M)

• Stage: Seed (positions itself as “seed-stage venture firm”)

• Core thesis: Vertical AI (AI-native solutions modernizing under-digitized “legacy” industries) + enterprise software

• Geography: “Investing globally,” but HQ + many proof points are U.S.-centric (healthcare, logistics, workforce, etc.).

Read more

Executive takeaways

• Fund III closed at $82.048M (oversubscribed) and is positioned as a lead pre-seed / seed vehicle writing $500K–$3M checks, with a stated focus on Vertical AI, Deep Tech, Healthcare, and Biotech, primarily in NYC and Boston.

• The firm has built a differentiated “speed + founder experience” posture via Pre-Seed Fast Track (commitment to “money in the bank” within 10 business days for eligible pre-seed rounds, typically $250K–$750K checks) and claims strong founder satisfaction (NPS).

• While Fund III is new, the franchise has multiple prior vintages (Fund I: $27M; Fund II: $67M) and can point to meaningful outcomes in the broader platform—e.g., Aerodome’s acquisition by Flock Safety and Alkami’s agreement to acquire MANTL for $400M EV.

• The most important LP diligence items, given the broader sector mandate (software + health/bio) and larger fund size, are: (1) net performance by vintage, (2) ownership + reserve policy, (3) ability to lead and maintain pro-rata in later rounds, and (4) team bandwidth/specialization across bio/health vs. software.

Read more

1) Executive takeaways for LPs

Read more

• Scale + momentum: Monroe announced a final close (Jan 6, 2026) for Fund V with $2.8B of institutional LP commitments, plus $1.5B of targeted fund-level leverage and $1.8B of SMAs in the same strategy—$6.1B total investable capital.

• Clear strategy positioning: Core focus remains senior secured direct lending to U.S. lower middle-market companies (~$35M EBITDA or less), across sponsored and select non-sponsored situations.

• Deployment is already material: As of Dec 31, 2025, the fund had committed >$3.2B across 130+ borrowers, implying meaningful early ramp and broad diversification.

• Ownership/strategic backing: Wendel and AXA IM Prime completed the acquisition of a controlling stake in Monroe on March 31, 2025, alongside an $800M sponsoring program and up to $200M GP commitment capital.

• Track record signals are strong but not a substitute for fund-level attribution: Wendel’s materials cite ~10% gross unlevered IRR (across fully exited companies) for Monroe’s directly originated transactions through Dec 31, 2024, and the Wendel deck cites ~1.5% default rate since inception and ~70% recovery on realized losses (firm-level).

Fund snapshot

Read more

Announced: Jan 9, 2026
Fund size (reported): $6.75B (largest fund in a16z’s newly announced ~$15B+ raise)

One-page takeaway

What it is: a16z’s fifth growth vehicle, focused on investing in more mature private companies (growth stage).
Why it matters: In an environment where VC fundraising has been challenged by low distributions, a16z’s ability to raise at scale is itself a market signal (brand + LP access + perceived opportunity set in AI).
Core question for LPs: Does a $6.75B growth fund improve your access to late-stage category leaders—or does it increase “megafund” risks (deployment, valuation, and exit timing)?

Read more